

CONTENTS

<i>Preface</i>	(vii)
<i>List of Abbreviations</i>	(xi)

CHAPTER 1

Introduction	1
---------------------------	---

CHAPTER 2

Literature Review

2.1 Introduction	3
2.2 Benefits and Usage of CAAT as a Cancer Therapeutic Agent....	4
2.2.1 A brief overview of Poly-L-Lysine and its advantage over the other amino acid	5
2.3 L-Lysine Help in the Treatment of Cancer.....	6
2.3.1 The anti-neoplastic activity of Poly-L-lysine	6
2.4 Antitumor Effect of Poly-L-Lysine as Combinational Therapy ..	7
2.4.1 On bladder cancer cell line	7
2.5 A Derivative of Poly-L-Lysine as a Natural Source.....	7
2.5.1 Epsilon-poly-l-lysine (ϵ -PL) from Streptomyces or Kitasatospora	7
2.6 Summary of Literature Review	7
2.7 Conclusion.....	9
<i>References</i>	11

CHAPTER 3

Aim and Objectives of the Study

3.1 Aim of the Study	24
3.2 The objectives of the Research Work.....	24
3.3 Organization of the Research Work	25

CHAPTER 4

General Remarks

4.1 Materials and Reagents Required for Experimental Studies	26
4.2 Cell Lines and Cell Culture	27
4.3 Animals for <i>in-vivo</i> Anti-Cancer Study	28

CHAPTER 5

Apoptosis Effect on EAC and in S-180 Tumour Model

5.1 Introduction	29
5.2 Preparation of the Drug Solution	31
5.3 <i>In-vitro</i> Experiment	31
5.3.1 MTT Assay	31
5.4 <i>In-vivo</i> Experiment	32
5.4.1 Experimental Design	32
5.4.2 EAC Peritoneal Tumour Model	33
5.4.2.1 Tumour Evaluation	33
5.4.2.2 Determination of Mean Survival Time and Percentage Increase in Lifespan	33
5.4.2.3 Estimation of Haematological and Serum Biochemical Parameters	33
5.4.2.4 Histopathology of Liver Tissue	34
5.4.2.5 Study on the Change in Morphology of EAC Cells by a Staining Method	34
5.4.2.6 Anti-Angiogenic Effects of the Compounds in Peritoneal Angiogenesis	34
5.4.2.7 Flow Cytometry using Annexin-V/PI	34
5.4.2.8 TUNEL Assay using Flow Cytometry	34
5.4.2.9 DNA Fragmentation Assay	35
5.4.2.10 DAPI Staining	35
5.4.2.11 Cell Cycle Analysis by Flow Cytometry	35
5.4.2.12 Western Blot Analysis	36

5.4.2.13	Sarcoma-180 Solid Tumour Model	36
5.4.2.14	Tumour volume	36
5.4.2.15	Tumour weight.....	37
5.4.2.16	Estimation of Haematological Blood Parameters.....	37
5.4.2.17	Percentage Increase in Lifespan (%ILS)	37
5.4.2.18	H & E Staining of Sarcoma-180 Tumour Section	37
5.4.2.19	Scanning Electron Microscopy (SEM) Study	37
5.4.2.20	Immunohistochemistry Study	38
5.4.2.21	Statistical Analysis.....	38
5.5	Results	38
5.5.1	<i>In-vitro</i> Study.....	38
5.5.1.1	Cell Viability Assay.....	38
5.5.2	<i>In-vivo</i> Study.....	39
5.5.2.1	PLL Inhibits Tumour Growth of EAC Cells	39
5.5.2.2	Effect of PLL on Haematological Parameters.....	40
5.5.2.3	Effect of PLL on Biochemical Parameters.....	40
5.5.2.4	Histopathology of Liver Tissue	43
5.5.2.5	Changes in the Morphology of EAC Cells ..	44
5.5.2.6	PLL Inhibits Peritoneal Angiogenesis on <i>in-vivo</i> Ehrlich Ascites Tumour Model	44
5.5.2.7	Apoptosis study by Annexin-V/PI assay	47
5.5.2.8	Study of Apoptosis in <i>in-vivo</i> EAC Cells by TUNEL Assay, DNA Fragmentation, and DAPI Staining	48
5.5.2.9	Cell Cycle Analysis by Flow Cytometry	49
5.5.2.10	Assessment of Protein Level Expression of PLL-Induced Apoptosis	49
5.5.2.11	PLL Inhibits Tumour Growth within Sarcoma-180 Solid Tumour.....	51
5.5.2.12	PLL Enhances the Survival of Sarcoma-180-bearing Mice.....	53

5.5.2.13	Effect of PLL on Histopathological Changes of Solid Sarcoma-180 Tumour.....	53
5.5.2.14	Scanning Electron Microscopy Analysis of Solid Sarcoma-180 Tumour	54
5.5.2.15	PLL Inhibits Tumour-Induced Neovascularisation in Sarcoma-180 Solid Tumour	55
5.5.2.16	PLL Induces apoptosis by Triggering the Expression of p53 and Bcl-2.....	56
5.6	Discussion.....	58
5.7	Conclusion.....	61
	<i>References</i>	61

CHAPTER 6

Evaluation of the Antioxidant and Antitumor Activity of Poly-L-Lysine in the Murine Malignant Tumour BALB/c Mice Model by Activating the Apoptosis

6.1	Introduction	65
6.2	Methods	66
6.2.1	Preparation of the Drug Solution.....	66
6.2.2	Determination of Median Lethal Dose (LD50)	66
6.2.3	Acute Toxicity Study and Behavioural Effects	67
6.2.4	Chronic Toxicity Study.....	67
6.2.5	<i>In-vitro</i> Experiment	67
6.2.5.1	MTT Assay	67
6.2.6	Experimental Design for <i>In Vivo</i> Studies	67
6.2.7	EAC Peritoneal Tumor Model.....	68
6.2.7.1	Tumor Evaluation	68
6.2.8	Determination of MST and %ILS.....	68
6.2.9	<i>In-vivo</i> MTT Assay.....	68
6.2.10	Trypan Blue Exclusion Test	69
6.2.11	Physiological Architecture Alterations Study.....	69

6.2.12	AO Staining	69
6.2.13	Study of Intracellular ROS	70
6.2.14	Liver Tissue Antioxidant Assay Parameters.....	70
6.2.15	Histopathology of Liver and Kidney Tissue.....	70
6.2.16	Protein Expression Evaluation.....	70
6.3	Results	70
6.3.1	<i>In-vitro</i> Cell Viability Assay	70
6.3.2	<i>In-vivo</i> Study.....	71
6.3.2.1	Determination of Drug Dose from Acute and Chronic Toxicity Studies.....	71
6.3.3	Effect of PLL on <i>In-Vivo</i> EAC Cell Viability	73
6.3.4	PLL Inhibits Tumour Growth of <i>In-Vivo</i> EAC Cells ...	74
6.3.5	PLL Enhances the Survival of EAC-Bearing Mice	75
6.3.6	Effect of PLL on Viability and Non-Viability of <i>In-Vivo</i> EAC Cells	75
6.3.7	Apoptotic Body Formation of EAC Cells Following PLL Medication.....	76
6.3.8	Induction of Apoptosis by PLL in <i>In-Vivo</i> EAC Cells	77
6.3.9	Quantification of Intracellular Reactive Oxygen Species (ROS) Accumulation Study.....	78
6.3.10	Effect of PLL on Haematological Parameters	79
6.3.11	Effect of PLL on Serum Biochemical Alteration in Serum of EAC-Bearing Mice	79
6.3.12	Effect of PLL on Liver Antioxidant Enzymes in EAC Inoculated BALB/c Mice.....	80
6.3.13	Histopathology of Liver and Kidney Tissue.....	81
6.3.14	PLL Potentiated the Apoptotic Effects in EAC Liquid Tumour <i>In-Vivo</i> Model	83
6.4	Discussion.....	84
6.5	Conclusion.....	85
	<i>References</i>	86

CHAPTER 7

The Effect of Anti-Propagation, Tumour-Angiogenic Repression and Down-Regulation of DAL Engendered Tumourigenesis by PLL

7.1 Introduction	88
7.1.1 Preparation of the drug Solution and Selection of Drug Dose by Acute Toxicity Study.....	89
7.1.2 HUVECs and DAL Proliferation Inhibition Assay	89
7.1.3 Study on Change in Morphology of DAL Cells by Giemsa Staining Method	90
7.1.4 Induction of DAL Solid Tumour	90
7.1.5 Tumour Volume.....	91
7.1.6 Tumour Weight.....	91
7.1.7 Estimation of Haematological and Serum Biochemical Parameters	91
7.1.8 Percentage Increase in Lifespan (%ILS)	91
7.1.9 H& E Staining of Sarcoma-180 Tumour Section	92
7.1.10 Immunohistochemistry Analysis	92
7.1.11 Western Blot Analysis	92
7.1.12 Statistical Analysis.....	92
7.2 Results	93
7.2.1 Poly-L-lysine Inhibited the Proliferation of HUVECs and DAL Cell	93
7.2.2 Changes in the Morphology of DAL Cells after PLL Treatment.....	94
7.2.3 Selection of Dosimetry of PLL for <i>In-Vivo</i> Experiments	94
7.2.4 Effect of PLL on Haematological Parameters	95
7.2.5 Effect of PLL on Biochemical Parameters	96
7.2.6 PLL Inhibits DAL Solid Tumour Growth in Mice	96
7.2.7 Effect of PLL Treatment on the Survival of Tumour-Bearing Mice	98
7.2.8 Effect of PLL on Histopathological Changes of Solid DAL Tumour.....	99

7.2.9 PLL Inhibits Tumour-Induced Neovascularisation in DAL Solid Tumour.....	100
7.2.10 PLL Administration Suppresses cell Proliferation and Induces Apoptosis in <i>In-Vivo</i> DAL Solid Tumour.....	102
7.2.11 PLL Attenuates the Expression of Cyclin-D1	104
7.2.12 PLL Potentiated the Anti-Tumour and Anti-Proliferative Effects in DAL Solid Tumour <i>In-Vivo</i> Model.....	104
7.3 Discussion.....	105
7.4 Conclusion.....	108
<i>References</i>	108

CHAPTER 8

Antiangiogenic Effect on B16F10 Tumour & 3D Cell Culture

8.1 Introduction	112
8.2 Methods	114
8.2.1 Preparation of the Drug Solution.....	114
8.2.2 Cell line and Cell Culture	114
8.2.3 B16F10 Proliferation Inhibition Assay.....	114
8.2.4 Induction of B16F10 Solid Murine Melanoma Cell and Evaluation of Tumour Volume and Weight .	114
8.2.5 Tumour Volume.....	114
8.2.6 Liver Tissue Antioxidant Assay Parameters.....	115
8.2.7 Histopathology of Liver and Kidney Tissue.....	115
8.2.8 Determination of MST and %ILS.....	115
8.2.9 Study of the Change in Morphology of B16F10 Tumourcells by Giemsa Staining Method	115
8.2.10 Immunohistochemistry Analysis	115
8.2.11 Protein Expression Assessment	116
8.2.12 Chicken Chorioallantoic Membrane (CAM) Assay ...	116

8.3	Result.....	116
8.3.1	PLL Hindered the Propagation of the B16F10 Tumour.....	116
8.3.2	PLL Prevents B16F10.....	117
8.3.3	Changes of PLL on Haematological Considerations ..	117
8.3.4	PLL Changes Biochemical Changes.....	118
8.3.5	Effect of PLL on Liver Antioxidant Enzymes in B16F10 Inoculated BALB/c Mice.....	118
8.3.6	Histopathology of Liver and Kidney Tissue.....	119
8.3.7	PLL Enhances the Survival of B16F10-Bearing Mice	121
8.3.8	Blood Parameters Study of B16F10 Tumour Holding PLL Treated Mice	122
8.3.9	Alterations Physiology of B16F10 Tumour Tissue Later PLL Medication.....	123
8.3.10	PLL Impedes Tumour-Encouraged Angiogenesis B16F10 Cancer Tissue.....	123
8.3.11	PLL Administration Suppresses Cell Proliferation in <i>In-Vivo</i> B16F10 Solid Tumour	124
8.3.12	PLL Impeded Angiogenesis CAM Prototype.....	125
8.3.13	PLL-Induced Caspase-3 Dependent Apoptosis in the 3D Tumour Microenvironment.....	126
8.3.14	PLL Inhibits Tumour Proliferation Marker Ki67 in the 3D Tumour Microenvironment.....	128
8.3.15	PLL Induce Oxidative Stress-Dependent SSBs DNA Break in the 3D Tumour Microenvironment	130
8.4	Discussion.....	132
8.5	Conclusion.....	135
	<i>References</i>	135

CHAPTER 9

Summary of Research Work

9.1	Evaluate the Induction of Apoptosis and Inhibition of Tumour Angiogenesis Effect on <i>In-Vivo</i> Murine Malignant Tumour Ehrlich Ascites Carcinoma and Sarcoma-180 Tumour Cells.....	139
-----	---	-----

9.2 Investiture of Apoptosis, Anti-Propagation,
Tumour-Angiogenic Inhibition and Down-Management of
DAL Engendered Tumourigenesis by Poly-L-Lysine:
A Systematic Research. 146

9.3 Poly-L-Lysine Inhibits Tumour Angiogenesis and
Induces Oxidative Stress-Dependent DNA Break and
Apoptosis in B16F10 Murine Melanoma Bearing BALB/c
Mice model and in 3D Physiological Relevant Breast
Cancer Model 149

CHAPTER 10

Conclusion 154

CHAPTER 11

Future Directions

11.1 Future Scope of Works 157

ANNEXURE 1

Types of Cancer 159

ANNEXURE 2

Classification of Anti-Cancer Drugs 165